These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15902566)

  • 21. [Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease].
    Engelbrecht V; Rassek M; Gärtner J; Kahn T; Mödder U
    Rofo; 1995 Sep; 163(3):238-44. PubMed ID: 7548871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long term clinical course of Canavan disease--a rare Japanese case].
    Mizuguchi K; Hoshino H; Hamaguchi H; Kubota M
    No To Hattatsu; 2009 Sep; 41(5):353-6. PubMed ID: 19764455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canavan disease: from spongy degeneration to molecular analysis.
    Matalon R; Michals K; Kaul R
    J Pediatr; 1995 Oct; 127(4):511-7. PubMed ID: 7562269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restricted diffusion in Canavan disease.
    Srikanth SG; Chandrashekar HS; Nagarajan K; Jayakumar PN
    Childs Nerv Syst; 2007 Apr; 23(4):465-8. PubMed ID: 17219235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preface: a brief review of N-acetylaspartate.
    Moffett JR; Namboodiri AM
    Adv Exp Med Biol; 2006; 576():vii-xiii. PubMed ID: 16802700
    [No Abstract]   [Full Text] [Related]  

  • 26. Canavan disease: a review of recent developments.
    Gordon N
    Eur J Paediatr Neurol; 2001; 5(2):65-9. PubMed ID: 11589315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.
    Janson CG; McPhee SW; Francis J; Shera D; Assadi M; Freese A; Hurh P; Haselgrove J; Wang DJ; Bilaniuk L; Leone P
    Neuropediatrics; 2006 Aug; 37(4):209-21. PubMed ID: 17177147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docking, molecular dynamics and free energy studies on aspartoacylase mutations involved in Canavan disease.
    Kocak A; Yildiz M
    J Mol Graph Model; 2017 Jun; 74():44-53. PubMed ID: 28349879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-acetylaspartic aciduria due to aspartoacylase deficiency--a new aetiology of childhood leukodystrophy.
    Hagenfeldt L; Bollgren I; Venizelos N
    J Inherit Metab Dis; 1987; 10(2):135-41. PubMed ID: 3116332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetylaspartic aciduria in Canavan disease: another proof in two infants.
    Yalaz K; Topçu M; Topaloğlu H; Gürçay O; Ozcan OE; Onol B; Renda Y
    Neuropediatrics; 1990 Aug; 21(3):140-2. PubMed ID: 2234319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
    Surendran S
    Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Canavan disease (aspartoacylase deficiency)].
    Kobayashi K; Tsujino S
    Ryoikibetsu Shokogun Shirizu; 2001; (36):118-21. PubMed ID: 11596340
    [No Abstract]   [Full Text] [Related]  

  • 33. [Canavan disease].
    Harting I; Seitz A
    Rofo; 2001 Oct; 173(10):M275-6. PubMed ID: 11710318
    [No Abstract]   [Full Text] [Related]  

  • 34. N-acetylaspartylglutamate in Canavan disease: an adverse effector?
    Burlina AP; Ferrari V; Divry P; Gradowska W; Jakobs C; Bennett MJ; Sewell AC; Dionisi-Vici C; Burlina AB
    Eur J Pediatr; 1999 May; 158(5):406-9. PubMed ID: 10333125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.
    Al-Dirbashi OY; Kurdi W; Imtiaz F; Ahmad AM; Al-Sayed M; Tulbah M; Al-Nemer M; Rashed MS
    Prenat Diagn; 2009 May; 29(5):477-80. PubMed ID: 19235826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case 15-1998: elevated N-acetylaspartic acid activity in Canavan's disease.
    Breslau J
    N Engl J Med; 1998 Aug; 339(9):636. PubMed ID: 9722443
    [No Abstract]   [Full Text] [Related]  

  • 37. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings.
    Zafeiriou DI; Kleijer WJ; Maroupoulos G; Anastasiou AL; Augoustidou-Savvopoulou P; Papadopoulou F; Kontopoulos EE; Fagan E; Payne S
    Brain Dev; 1999 Apr; 21(3):205-8. PubMed ID: 10372908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canavan disease and N-acetylaspartic aciduria.
    Elpeleg ON; Amir N; Barash V; Glick B; Gross-Tsur V; Shachar E; Shapira Y; Tzelnik N
    Neuropediatrics; 1989 Nov; 20(4):238. PubMed ID: 2608171
    [No Abstract]   [Full Text] [Related]  

  • 40. In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T.
    Blüml S
    J Magn Reson; 1999 Feb; 136(2):219-25. PubMed ID: 9986765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.